Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +972-77-2005042 from 8 AM - 11 PM IL

    • Contact
    • Contact

      +972-77-2005042
      from 8 AM - 11 PM IL

  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR
  • Request More Information
  • Journalists
  • GDPR

Synchrony Medical Enrolling Bronchiectasis Patients in Real-World Study to Evaluate Impact of LibAirty™ Airway Clearance System


News provided by

Synchrony Medical

11 Aug, 2026, 15:00 IDT

Share this article

Share toX

Share this article

Share toX

12-Month Observational Study at Leading U.S. Respiratory Centers Will Assess Clinical Impact of Independent Home Use of the LibAirty™ System

JERSEY CITY, N.J. and OR YEHUDA, Israel, Aug. 11, 2026 /PRNewswire/ -- Synchrony Medical, a respiratory care technology company and creator of the FDA-cleared LibAirty™ Airway Clearance System, today announced that RELACS (Real Life Evaluation of the LibAirty™ Airway Clearance System in Adults with Bronchiectasis) is actively enrolling patients at leading U.S. respiratory care centers, including the Medical University of South Carolina, the University of Alabama at Birmingham, and Emory University School of Medicine - Pulmonary Clinic in Atlanta. The 12-month prospective observational study is evaluating how integrating LibAirty™ into routine, home-based therapy affects the health outcomes and quality of life for people living with bronchiectasis, compared to each participant's prior 12-month medical history.

Bronchiectasis is a chronic lung condition in which damaged, widened airways lead to mucus accumulation in the lungs, driving a cycle of persistent cough, recurrent infections, and long-term decline in lung function. For the hundreds of thousands of Americans living with the condition, daily airway clearance is a vital line of defense—helping remove trapped mucus to reduce symptoms, prevent repeated infections, slow disease progression, and restore quality of life.

LibAirty™ is an airway clearance system designed to make daily home therapy simple and effective. Based on the principles of autogenic drainage, a clinically proven airway clearance technique, the device delivers targeted chest pressure synchronized with app-guided breathing coaching, enabling patients to easily experience therapy independently at home. Earlier clinical studies at Sheba Medical Center and the Medical University of South Carolina found that patients cleared twice as much sputum with LibAirty™ compared to traditional vest-based therapy, while reporting higher comfort and satisfaction1.

"Maintaining daily airway clearance at home is a constant struggle for people with bronchiectasis," said Dr. Patrick Flume, Director of the Adult Cystic Fibrosis Center at MUSC Health. "Since introducing LibAirty™, the feedback has been very positive. Patients are reporting better lung clearance with improved comfort and ease. The RELACS study enables us to capture these observations and evaluate their impact on long-term clinical outcomes over a full year of independent use."

"LibAirty™ was designed to empower people living with chronic lung conditions to take control of their health at home," said Anat Shani, Co-Founder & CEO of Synchrony Medical. "Advancing the RELACS study across top-tier U.S. respiratory centers is an important step in our mission to expand access to effective, patient-centered technology, backed by real-world evidence."

More information about the study can be found at ClinicalTrials.gov (Identifier: NCT07135284).

About Synchrony Medical

Synchrony Medical is a respiratory care technology company dedicated to providing advanced at-home airway clearance therapy. The company's FDA-cleared LibAirty™ Airway Clearance System is designed to transform respiratory therapy into an easy-to-manage daily routine that patients can perform independently at home and elevate the standard of care for those living with chronic lung disease. Developed in collaboration with leading pulmonologists at Sheba Medical Center, LibAirty™ was founded through Edge Medical Ventures' EdgeLabs (formerly MEDX Xelerator). Synchrony Medical is headquartered in Jersey City, New Jersey, with additional operations in Or Yehuda, Israel. For more information, visit https://libairty.health/.

  1. Helper N, Ashkenazi M, Sokol G, Dagan A, Efrati O. A Novel Medical Device for Airway Clearance. J Clin Med. 2025 Jan 30;14(3):907.
    Mingora C, Barfield W, Shani A, Tzfoni T, Flume P. Evaluation of the Safety and Efficacy of LibAirtyTM Airway Clearance System in Patients with Bronchiectasis. Presented at The American College of Chest Physicians (CHEST) Annual Meeting 2023.

Media Contact:
Aviva Sapir
Number 10 Strategies
[email protected]

SOURCE Synchrony Medical

Modal title

Also from this source

Synchrony Medical Secures $5M Funding to Fuel Commercial Expansion of its At-Home Airway Clearance Device for Chronic Respiratory Disease

Synchrony Medical, a respiratory care technology company and creator of the FDA-cleared LibAirty™ Airway Clearance System, today announced it has...

Synchrony Medical Secures Investment from New Jersey Innovation Evergreen Fund (NJIEF) to Scale LibAirty™ Airway Clearance System Nationwide

Synchrony Medical, a respiratory care technology company and creator of the FDA-cleared LibAirty™ airway clearance system, today announced it has...

More Releases From This Source

Explore

Medical Equipment

Medical Equipment

Medical Pharmaceuticals

Medical Pharmaceuticals

Biotechnology

Biotechnology

Health Care & Hospitals

Health Care & Hospitals

News Releases in Similar Topics

Contact PR Newswire

  • +972-77-2005042
    from 8 AM - 11 PM IL

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Csezh
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italie
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+972-77-2005042
from 8 AM - 11 PM IL
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2026 Cision US Inc.